NUMA1 and neoplasm: Early FDA-approved assays, including Nuclear Matrix Protein 22 (NMP22), Bladder Tumor Antigen Stat and TRAK (BTA Stat/TRAK), Immunocytochemical Assay (ImmunoCyt/uCyt+), and the UroVysion fluorescence in situ hybridization (FISH) test, improved sensitivity but lacked sufficient specificity.